The American Journal of Surgery
Volume 187, Issue 3 , Pages 349-362 , March 2004

Current comprehensive assessment and management of women at increased risk for breast cancer

  • Alan B Hollingsworth, M.D.

      Affiliations

    • Department of Surgery, Mercy Health Center, Mercy Women's Center, 4300 McAuley Blvd., Oklahoma City, OK 73120, USA
    • Corresponding Author InformationCorresponding author. Tel.: +1-405-936-5455; fax: +1-405-936-5217.
    • ,
  • S.Eva Singletary, M.D.

      Affiliations

    • Department of Surgery, MD Anderson Cancer Center, Houston, TX, USA
    • ,
  • Monica Morrow, M.D.

      Affiliations

    • Department of Surgery, Northwestern University, Chicago, IL, USA
    • ,
  • Darius S Francescatti, M.D.

      Affiliations

    • Department of Surgery, Rush Medical College, Chicago, IL, USA
    • ,
  • Joyce A O'Shaughnessy, M.D.

      Affiliations

    • Baylor-Sammons Cancer Center, US Oncology, Dallas, TX, USA
    • ,
  • Anne-Renee Hartman, M.D.

      Affiliations

    • Department of Medicine, Dana–Farber Cancer Institute, Harvard Medical School, Boston, MA, USA
    • ,
  • Becky Haddad, M.T.

      Affiliations

    • Susan G. Komen Foundation, Dallas, TX, USA
    • ,
  • Freya R Schnabel, M.D.

      Affiliations

    • Department of Surgery, Columbia Presbyterian Medical Center, New York, NY, USA
    • ,
  • Victor G Vogel, M.D.

      Affiliations

    • Department of Medicine, University of Pittsburgh, Pittsburgh, PA, USA

Received 29 January 2003 ,Revised 18 May 2003

References 

  1. Fisher B, Costantino JP, Wickerham DL, et al.  Tamoxifen for prevention of breast cancer (report of the National Surgical Adjuvant Breast and Bowel Project P-1 study). J Natl Cancer Inst. 1998;90:1371–1388
  2. Hartmann LC, Schaid DJ, Woods JE, et al.  Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer. N Engl J Med. 1999;340:77–84
  3. Rebbeck TR. Prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers. J Clin Oncol. 2000;18(suppl):100–103
  4. Grann VR, Jacobson JS, Thomason D, et al.  Effect of prevention strategies on survival and quality-adjusted survival of women with BRCA 1/2 mutations (an updated decision analysis). J Clin Oncol. 2002;20:2520–2529
  5. O'Shaughnessy JA, Ljung BM, Dooley WC, et al.  Ductal lavage and the clinical management of women at high risk for breast carcinoma. Cancer. 2002;94:292–298
  6. Brinton LA, Schairer C, Hoover RN, Fraumeni JF. Menstrual factors and risk of breast cancer. Cancer Investigation. 1988;6:245–254
  7. Trichopoulos D, MacMahon B, Cole P. Menopause and breast cancer risk. J Natl Cancer Inst. 1972;48:605–613
  8. Ursin G, Tseng C-C, Paganini-Hill A, et al.  Does menopausal hormone replacement therapy interact with known factors to increase risk of breast cancer?. J Clin Oncol. 1992;20:699–706
  9. Tretli S. Height and weight in relation to breast cancer morbidity and mortality (a prospective study of 570,000 women in Norway). Int J Cancer. 1989;44:23–30
  10. Longnecker MP, Berlin JA, Orza MJ, Chalmers TC. A meta-analysis of alcohol consumption in relation to risk of breast cancer. JAMA. 1988;260:652–656
  11. Sattin RW, Rubin GL, Webster LA, et al.  Family history and the risk of breast cancer. JAMA. 1985;253:1908–1913
  12. Gail MH, Brinton LA, Byar DP, et al.  Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J Natl Cancer Inst. 1989;81:1879–1886
  13. Sharpe CR. A development hypothesis to explain the multicentricity of breast cancer. Can Med Assoc J. 1998;159:55–59
  14. Clemons M, Loijens L, Goss P. Breast cancer risk following irradiation for Hodgkin's disease. Cancer Treat Rev. 2000;26:291–302
  15. Page DL, Dupont WD, Rogers LW, Landenberger M. Intraductal carcinoma of the breast: follow-up after biopsy only. Cancer 1982;751–8
  16. Hutter RV. The management of patients with lobular carcinoma in situ of the breast. Cancer. 1984;53:2–798
  17. Singletary SE. A working model for the time sequence of genetic changes in breast tumorigenesis. J Am Coll Surg. 2002;194:202–216
  18. Dupont WD, Page DL. Risk factors for breast cancer in women with proliferative breast disease. N Engl J Med. 1985;312:146–151
  19. Wrensch MR, Petrakis NL, King EB, et al.  Breast cancer incidence in women with abnormal cytology in nipple aspirates of breast fluid. Am J Epidemiol. 1992;135:130–141
  20. Fabian CJ, Kimler BF, Zalles CM, et al.  Short-term breast cancer prediction by random periareolar fine-needle aspiration cytology and the Gail risk model. J Natl Cancer Inst. 2000;92:1217–1227
  21. King EB, Chew KL, Petrakis NL, Ernster VL. Nipple aspirate cytology for the study of breast cancer precursors. J Natl Cancer Inst. 1983;71:1115–1121
  22. Krishnamurthy S, Sneige N, Thompson PA, et al. Nipple aspirate fluid cytology in breast cancer. Cancer 2003;99:97–104
  23. Keating NL, Cleary PD, Rossi AS, et al.  Use of hormone replacement therapy by postmenopausal women in the United States. Ann Intern Med. 1999;130:545–553
  24. Collaborative Group on Hormonal Factors in Breast Cancer . Breast cancer and hormone replacement therapy (collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer). Lancet. 1997;350:1047–1059
  25. Schairer C, Lubin J, Troisi S, et al.  Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk. JAMA. 2000;283:485–491
  26. Ross RK, Paganini-Hill A, Wan PC, Pike NC. Effect of hormone replacement therapy on breast cancer risk (estrogen versus estrogen plus progestin). J Natl Cancer Inst. 2000;92:328–332
  27. Writing Group for the Women's Health Initiative Investigators . Risks and benefits of estrogen plus progestin in healthy postmenopausal women. Principal results from the Women's Health Initiative randomized controlled trial. JAMA. 2002;288:321–333
  28. Gapstur SM, Morrow M, Sellers TA. Hormone replacement therapy and breast cancer with a favorable pathology. JAMA. 1999;281:2091–2097
  29. Jordan VC, Morrow M. Editorial. Raloxifene as a multifunctional medicine?. BMJ. 1999;319:331–332
  30. Vogel VG. Assessing potential risk of developing breast cancer. Oncology. 1996;10:1451–1461
  31. London SJ, Connolly JL, Schnitt SJ, et al.  A prospective study of benign breast disease and the risk of breast cancer. JAMA. 1992;267:941–944
  32. Vogel VG. High-risk populations as targets for breast cancer prevention trials. Prev Med. 1991;20:86–100
  33. Costantino JP, Gail MH, Pee D, et al.  Validation studies for models projecting the risk of invasive and total breast cancer incidence. J Natl Cancer Inst. 1999;91:1541–1548
  34. Bondy ML, Lustbader ED, Halabi S, et al.  Validation of a breast cancer risk assessment model in women with a positive family history. J Natl Cancer Inst. 1994;86:620–625
  35. Claus E, Risch N, Thompson WD. The calculation of breast cancer risk for women with a first degree family history of ovarian cancer. Breast Cancer Res Treat. 1993;28:115–120
  36. Rockhill B, Spiegelman D, Byrne C, et al.  Validation of the Gail et al model of breast cancer risk prediction and implications for chemoprevention. J Natl Cancer Inst. 2001;93:358–366
  37. Claus EB, Risch N, Thompson WD. Autosomal dominant inheritance of early-onset breast cancer. Implications for risk prediction. Cancer. 1994;73:643–651
  38. Couch FJ, DeShano ML, Blackwood A, et al.  BRCA1 mutations in women attending clinics that evaluate the risk of breast cancer. N Engl J Med. 1997;336:1409–1415
  39. Shattuck-Eidens D, McClure M, Simard J, et al.  A collaborative survey of 80 mutations in the BRCA1 breast and ovarian cancer susceptibility gene (implications for presymptomatic testing and screening). JAMA. 1995;273:535–541
  40. Frank TS, Deffenbaugh AM, Hulick M, et al.  Hereditary susceptibility to breast cancer (significance of age of onset in family history and contribution of BRCA1 and BRCA2). Dis Markers. 1999;15:89–92
  41. Berry DA, Iversen ES, Gudbjartsson DF, et al.  BRCAPRO validation, sensitivity of genetic testing of BRCA1/BRCA2, and prevalence of other breast cancer susceptibility genes. J. Clin Oncol. 2002;20:2701–2712
  42. Vogel VG, editor. Management of Patients at High Risk for Breast Cancer. Malden, MA: Blackwell Science, 2001
  43. Wellings SR. A hypothesis of the origin of human breast cancer from the terminal ductal lobular unit. Pathol Res Pract. 1980;166:515–535
  44. Hutchinson WB, Thomas DB, Hamlin WB, et al.  Risk of breast cancer in women with benign breast disease. J Natl Cancer Inst. 1980;65:13–20
  45. Dooley WC, Ljung BM, Veronesi U, et al.  Ductal lavage for detection of cellular atypia in women at high risk for breast cancer. J Natl Cancer Inst. 2001;93:1624–1632
  46. Petricoin EF, Ornstein DK, Paweletz CP, et al.  Serum proteomic patterns for detection of prostate cancer. J Natl Cancer Inst. 2002;94:1576–1578
  47. Morrow M, Vogel V, Ljung BM, O'Shaughnessy JA. Evaluation and management of the woman with an abnormal ductal lavage. J Am Coll Surg. 2002;194:648–656
  48. Page DL, Dupont WD, Rogers LW, et al.  Atypical hyperplastic lesions of the female breast (a long-term follow-up study). Cancer. 1985;55:2698–2708
  49. Wrensch MR, Petrakis NL, Miike R, et al.  Breast cancer risk in women with abnormal cytology in nipple aspirates of breast fluid. J Natl Cancer Inst. 2001;93:1791–1798
  50. Colditz GA, Rosner B. Cumulative risk of breast cancer to age 70 years according to factor status (data from the Nurses' Health Study). Am J Epidemiol. 2000;152:950–964
  51. Fisher B, Dignam J, Wolmark N, et al.  Tamoxifen in treatment of intraductal breast cancer (National Surgical Adjuvant Breast and Bowel Project B-24 randomized controlled trial). Lancet. 1999;353:1993–2000
  52. Fisher B, Costantino J, Redmond C, et al.  A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors. N Engl J Med. 1989;320:479–484
  53. Easton DF, Ford BP, Bishop DT  Breast Cancer Linkage Consortium . Breast and ovarian cancer incidence in BRCA1-mutation carriers. Am J Hum Genet. 1995;56:265–271
  54. van Leeuwen FE, Klokman WJ, Hagenbeek A, et al.  Second cancer risk following Hodgkin's disease (a 20-year follow-up study). J Clin Oncol. 1994;12:312–325
  55. Smith RA, Cokkinides V, von Eschenbach AC, et al.  American Cancer Society guidelines for the early detection of cancer. CA Cancer J Clin. 2002;52:8–22
  56. Cummings SR, Eckert S, Krueger KA, et al.  The effect of raloxifene on risk of breast cancer in postmenopausal women. Results from the MORE randomized trial. JAMA. 1999;281:2189–2197
  57. Vogel VG, Costantino JP, Wickerham DL, et al. The study of tamoxifen and raloxifene: preliminary enrollment data from a randomized breast cancer risk reduction trial. Clin Breast Cancer 2002;3:153–9
  58. Chlebowski RT, Col N, Winer EP, et al.  American Society of Clinical Oncology technology assessment of pharmacologic interventions for breast cancer risk reduction including tamoxifen, raloxifene, and aromatase inhibition. J Clin Oncol. 2002;20:3328–3343
  59. Fletcher SW, Colditz GA. Failure of estrogen plus progestin therapy for prevention. JAMA. 2002;288:366–368
  60. Eisen A, Rebbeck TR, Wood WC, Weber BL. Prophylactic surgery in women with a hereditary predisposition to breast and ovarian cancer. J Clin Oncol. 2000;18:1980–1995
  61. Kinsinger LS, Harris R, Woolf SH, et al.  Chemoprevention of breast cancer (a summary of the evidence for the U.S. Prevention Services Task Force). Ann Intern Med. 2002;137:59–67
  62. King MC, Wieand S, Hale K, et al.  Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA1 and BRCA2 (National Surgical Adjuvant Breast and Bowel Project (NSABP-P1) breast cancer prevention trial). JAMA. 2001;286:2251–2256
  63. Narod SA, Brunet JS, Gharirian P, et al.  Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers (a case control study. Hereditary Breast Cancer Clinical Study Group). Lancet. 2000;356:1876–1881
  64. Kauff ND, Satagopan JM, Robson ME, et al.  Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med. 2002;346:1609–1615
  65. Rebbeck TR, Lynch HT, Neuhausen SL, et al.  Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N Engl J Med. 2002;346:1616–1622
  66. Weinreb JC, Newstead G. MR imaging of the breast. Radiology. 1995;196:593–610
  67. Harms SE. Breast magnetic resonance imaging. Semin Ultra-sound CT MR. 1998;19:104–120
  68. Lynch HT, Albano WA, Danes BS, et al.  Genetic predisposition to breast cancer. Cancer. 1984;53:612–622
  69. Ford D, Easton DF, Stratton M, et al.  Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. Am J Hum Genet. 1998;62:676–689
  70. Struewing JP, Hartage P, Wacholder S, et al.  The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med. 1997;336:1401–1408
  71. Schrag D, Kuntz KM, Garber JE, Weeks JC. Decision analysis—effects of prophylactic mastectomy and oophorectomy on life expectancy among women with BRCA1 or BRCA2 mutations. N Engl J Med. 1997;336:1465–1471
  72. Hartmann LC, Sellers TA, Schaid DJ, et al.  Efficacy of bilateral prophylactic mastectomy in BRCA1 and BRCA2 gene mutation carriers. J Natl Cancer Inst. 2001;93:1633–1637
  73. Harms SE, Flamig DP. MR imaging of the breast. J Magn Reson Imaging. 1993;3:277–283
  74. Kaiser WA, Zeitler E. MR imaging of the breast (fast imaging sequences with and without Gd-DTPA. Preliminary observations). Radiology. 1989;170:681–686
  75. Orel SG, Schnall MD, Powell CM, et al.  Staging of suspected breast cancer (effect of MR imaging and MR-guided biopsy). Radiology. 1995;196:115–122
  76. Tilanus-Linthorst MM, Obdeijn IM, Bartels KC, et al.  First experiences in screening women at high risk for breast cancer with MR imaging. Breast Cancer Res Treat. 2000;63:53–60
  77. Kuhl CK, Schmutzler RK, Leutner CC, et al.  Breast MR imaging screening in 192 women proved or suspected to be carriers of a breast cancer susceptibility gene (preliminary results). Radiology. 2000;215:267–279
  78. Brown J, Buckley D, Coulthard A, et al.  Magnetic resonance imaging screening in women at genetic risk of breast cancer (imaging and analysis protocol for the UK multicentre study. UK MRI breast Screening Study Advisory Group). Magn Reson Imaging. 2000;18:765–776
  79. Warner E, Plewes DB, Shumak RS, et al.  Comparison of breast magnetic resonance imaging, mammography, and ultrasound for surveillance of women at high risk for hereditary breast cancer. J Clin Oncol. 2001;19:3524–3531
  80. Stoutjesdijk MJ, Boetes C, Jager GJ, et al.  Magnetic resonance imaging and mammography in women with a hereditary risk of breast cancer. J Natl Cancer Inst. 2001;93:1095–1102
  81. Warner E, Plewes DB, Hill K, et al.  Three year results of annual breast magnetic resonance imaging (MRI) and ultrasound (US) in addition to mammography and clinical breast examination for surveillance of women at high risk for hereditary breast cancer. Proc Am Soc Clin Oncol. 2002;21:1704
  82. Prochaska JO. Treating entire populations for behavior risks for cancer. Cancer J. 2001;7:360–368
  83. Vogel VG, Costantino JP, Wickerham DL, Cronin WM. Tamoxifen for prevention of breast cancer (report of the National Surgical Adjuvant Breast and Bowel Project P-1 study). J Natl Cancer Inst. 2002;94:1504

PII: S0002-9610(03)00604-4

doi: 10.1016/j.amjsurg.2003.12.025

The American Journal of Surgery
Volume 187, Issue 3 , Pages 349-362 , March 2004

Article Tools

* Image Usage & Resolution